<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267029</url>
  </required_header>
  <id_info>
    <org_study_id>TADPOL_v0.7</org_study_id>
    <nct_id>NCT04267029</nct_id>
  </id_info>
  <brief_title>Transfusion Associated Dyspnea Profiling</brief_title>
  <acronym>TADPOL</acronym>
  <official_title>Transfusion-Associated Dyspnea: Prospective Observational and Laboratory Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toronto Transfusion Medicine Collaborative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MOUNT SINAI HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Toronto Transfusion Medicine Collaborative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transfusion reactions are defined as harms occurring during or after blood transfusion, with&#xD;
      new heart/lung stress (eg. troubled breathing) regarded as cardiorespiratory transfusion&#xD;
      reactions (CRTRs). CRTRs are among the most important, as the leading cause of&#xD;
      transfusion-related harm and death. Though there are distinct classifications for these&#xD;
      events, real life cases often don't fall neatly into a given category, with outliers regarded&#xD;
      as &quot;transfusion associated dyspnea (TAD)&quot;. It is unknown what TAD is -- whether it has a&#xD;
      unique root cause, is a milder version of other known CRTRs, or is a blend of events. The&#xD;
      purpose of this study is to better understand TAD and CRTRs by profiling them through a&#xD;
      detailed medical history and more intensive laboratory assessment. This review of CRTRs may&#xD;
      improve the quality/validity of final conclusions reported in the health record and to&#xD;
      hemovigilance bodies, and uncover the nature of TAD and/or minimize CRTRs defaulting to the&#xD;
      TAD category. Our enhanced understanding will advance diagnostic, treatment, and prevention&#xD;
      efforts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Transfusion-Associated Dyspnea: Prospective Observation and Laboratory Assessment&quot; (TADPOL)&#xD;
      aims to improve the diagnosis and characterization of cardiorespiratory transfusion reaction&#xD;
      (CRTR) patients (&quot;cases&quot;), as compared with high risk febrile transfusion reaction (HRFTR)&#xD;
      patients (&quot;controls&quot;), by applying a standardized and intensive clinicolaboratory profiling&#xD;
      tool.&#xD;
&#xD;
      CRTR, in contrast with HRFTR, are more difficult to diagnose and manage. Patients are often&#xD;
      sick with (or prone to) pathologies that resemble reactions (eg. congestive heart failure&#xD;
      [CHF] vs transfusion associated circulatory overload [TACO]), and/or experience more than one&#xD;
      transfusion-associated disturbance at a time.&#xD;
&#xD;
      CRTRs are also the most disruptive, distressing, and disposition-escalating events for&#xD;
      patients at an individual level, and are disproportionately accountable for transfusion&#xD;
      associated deaths at the collective level in national hemovigilance systems. The cardinal&#xD;
      CRTRs range from TACO (most commonly) to allergic bronchospasm to transfusion related acute&#xD;
      lung injury (TRALI).&#xD;
&#xD;
      Inaccurate classification may undercount certain phenomena (when criteria fail to be met by&#xD;
      confounding conditions), and/or overcount others (when including all&#xD;
      possibilities-of-relevance in hemovigilance).&#xD;
&#xD;
      These uncertainties beget gaps (or excesses) in patient care and in donor/product-associated&#xD;
      decision-making.&#xD;
&#xD;
      HYPOTHESES: The TADPOL CRF and laboratory profiling effort will improve the yields of&#xD;
      confident (more certain), accurate (better-grounded), and thorough (multi-event-sensitive)&#xD;
      diagnoses in CRTR patients.&#xD;
&#xD;
      Most cases of TAD are likely to be re-classified as milder versions (or overlaps) of possible&#xD;
      CRTR states (± the underlying condition), while the remainder may exhibit a signature&#xD;
      resembling FNHTR (FTR controls).&#xD;
&#xD;
      Precise case-mapping should yield useful personalized information, while aggregated findings&#xD;
      from each disturbance pathway - as they are distributed in each conventional reaction&#xD;
      category - can validate the utility of markers being explored in reaction investigation&#xD;
      algorithms.&#xD;
&#xD;
      The TADPOL bioarchive and anonymized dataset will also be assets for explorations of novel&#xD;
      indicators and patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CERTAINTY</measure>
    <time_frame>2 years</time_frame>
    <description>Improve certainty in final cardiorespiratory transfusion reaction event classifications (by reduction in the number of cases otherwise achieving no better than &quot;possible&quot; provisional conclusions), from the expected base ambiguity rate of 60%, down to 30%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COMPLEXITY</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the frequency of multi-domain disturbances (ie- &quot;overlap&quot;) in cardiorespiratory transfusion reaction referrals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATHOGENESIS FOOTPRINTING</measure>
    <time_frame>2 years</time_frame>
    <description>Statistically characterize concordance of established and potential criteria in TRALI, TACO, allergic bronchospasm, and TAD</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transfusion Reaction</condition>
  <arm_group>
    <arm_group_label>Cases: CRTR (cardiorespiratory transfusion reaction)</arm_group_label>
    <description>Respiratory/cardiovascular disturbances after transfusion (&gt;/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls: HRFTR (high risk febrile transfusion reactions)</arm_group_label>
    <description>Post-transfusion fevers requiring laboratory investigation (Tmax&gt;/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TADPOL battery (deep clinicolaboratory profile)</intervention_name>
    <description>profile dimensions:&#xD;
hemolytic&#xD;
allergic&#xD;
cardiorenal&#xD;
inflammatory&#xD;
leukoagglutinating&#xD;
exploratory bioarchive</description>
    <arm_group_label>Cases: CRTR (cardiorespiratory transfusion reaction)</arm_group_label>
    <arm_group_label>Controls: HRFTR (high risk febrile transfusion reactions)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Post-reaction plasma and serum and cellular pellets Implicated blood product residua&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients at 4 university-affiliated teaching hospitals who have received a blood&#xD;
        transfusion, and experienced a suspected acute transfusion reaction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Transfusion of blood products (components or derivatives) with an available&#xD;
             pre-transfusion group &amp; screen specimen&#xD;
&#xD;
          -  Referred to the blood transfusion laboratory for review of a suspected acute&#xD;
             transfusion reaction (occurring within 24 hours of completing transfusion), and either&#xD;
             exhibiting a cardiorespiratory disturbance (CRTR: cases) or a high-risk febrile&#xD;
             disturbance (HRFTR: controls)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Massive hemorrhage entailing &gt;20 implicated products in the 24h period before the&#xD;
             acute transfusion reaction's onset&#xD;
&#xD;
          -  Previous enrolment in the same designation (ie- an individual with RTR will not&#xD;
             re-enroll if having another RTR, but may re-enrol if having FTR)&#xD;
&#xD;
          -  Expected to discharge home or die sooner than specimen acquisition&#xD;
&#xD;
          -  Withdrawal of consent at any time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M Csert-Gazdewich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universith Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samia Saeed, BSc</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>2892</phone_ext>
    <email>Samia.Saeed@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omar Florez</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8116</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Armali</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>85179</phone_ext>
      <email>Chantal.Armali@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Jeannie Callum</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Yulia Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samia Saeed, BSc</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>2892</phone_ext>
      <email>Samia.Saeed@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Dr.Christine Cserti-Gazdewich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samia Saeed, BSc</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>2892</phone_ext>
      <email>Samia.Saeed@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Nadine Shehata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aziz Jiwajee</last_name>
      <phone>(416) 864-5354</phone>
      <email>jiwajeeA@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Katerina Pavenski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>McVey MJ, Cohen R, Arsenault V, Escorcia A, Tasmin F, Pendergrast J, Lieberman L, Lin Y, Callum J, Cserti-Gazdewich C. Frequency and timing of all-cause deaths in visits involving suspected transfusion reactions, and the significance of cardiopulmonary disturbances. Vox Sang. 2021 Sep;116(8):898-909. doi: 10.1111/vox.13086. Epub 2021 Feb 26.</citation>
    <PMID>33634884</PMID>
  </reference>
  <results_reference>
    <citation>Callum JL, Cohen R, Cressman AM, Strauss R, Armali C, Lin Y, Pendergrast J, Lieberman L, Scales DC, Skeate R, Ross H, Cserti-Gazdewich C. Cardiac stress biomarkers after red blood cell transfusion in patients at risk for transfusion-associated circulatory overload: a prospective observational study. Transfusion. 2018 Sep;58(9):2139-2148. doi: 10.1111/trf.14820.</citation>
    <PMID>30204946</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Escorcia A, Tasmin F, Lima A, Lin Y, Lieberman L, Pendergrast J, Callum J, Cserti-Gazdewich C. Feeling the burn: the significant burden of febrile nonhemolytic transfusion reactions. Transfusion. 2017 Jul;57(7):1674-1683. doi: 10.1111/trf.14099. Epub 2017 Mar 28.</citation>
    <PMID>28369916</PMID>
  </results_reference>
  <results_reference>
    <citation>Cserti-Gazdewich C, Escorcia A, Pendergrast J, Lieberman L, Skeate R, Lin Y, Callum J. Platelet transfusion reactions do not occur more often in recipients transfused with apheresis versus buffy coat platelet concentrates. Transfusion. 2016 Dec;56(12):3144-3146. doi: 10.1111/trf.13884.</citation>
    <PMID>27933620</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodwin J, Tinckam K, denHollander N, Haroon A, Keshavjee S, Cserti-Gazdewich CM. Transfusion-related acute lung injury (TRALI) in graft by blood donor antibodies against host leukocytes. J Heart Lung Transplant. 2010 Sep;29(9):1067-70. doi: 10.1016/j.healun.2010.04.019. Epub 2010 Jun 8.</citation>
    <PMID>20627626</PMID>
  </results_reference>
  <results_reference>
    <citation>Hart S, Cserti-Gazdewich CM, McCluskey SA. Red cell transfusion and the immune system. Anaesthesia. 2015 Jan;70 Suppl 1:38-45, e13-6. doi: 10.1111/anae.12892. Review.</citation>
    <PMID>25440393</PMID>
  </results_reference>
  <results_reference>
    <citation>McVey MJ, Lin Y, Young DK, Cserti-Gazdewich C. A case of recurrent transfusion-related acute lung injury despite lessons learned from antibody mitigation. Transfus Med. 2019 Oct;29(5):376-378. doi: 10.1111/tme.12628. Epub 2019 Aug 19.</citation>
    <PMID>31429144</PMID>
  </results_reference>
  <results_reference>
    <citation>Parmar N, Pendergrast J, Lieberman L, Lin Y, Callum J, Cserti-Gazdewich C. The association of fever with transfusion-associated circulatory overload. Vox Sang. 2017 Jan;112(1):70-78. doi: 10.1111/vox.12473. Epub 2016 Dec 21.</citation>
    <PMID>28001310</PMID>
  </results_reference>
  <results_reference>
    <citation>Pendergrast J, Armali C, Cserti-Gazdewich C, Hansen M, Kiss A, Lieberman L, Parmar N, Scales D, Skeate R, Callum J, Lin Y. Can furosemide prevent transfusion-associated circulatory overload? Results of a pilot, double-blind, randomized controlled trial. Transfusion. 2019 Jun;59(6):1997-2006. doi: 10.1111/trf.15270. Epub 2019 Mar 28.</citation>
    <PMID>30924166</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen R, Lima A, Escorcia A, Tasmin F, Lin Y, Lieberman L, Pendergrast J, Callum J, Cserti-Gazdewich C. Serologic assessments in acute transfusion reactions: practices and yields. Vox Sang. 2019 Oct;114(7):749-761. doi: 10.1111/vox.12830. Epub 2019 Aug 7.</citation>
    <PMID>31392749</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TACO (transfusion associated circulatory overload)</keyword>
  <keyword>TRALI (transfusion related acute lung injury)</keyword>
  <keyword>Allergic Reaction</keyword>
  <keyword>FNHTR (febrile non-hemolytic transfusion reaction)</keyword>
  <keyword>TAD (transfusion associated dyspnea)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

